Table 4 Summary of published or ongoing prospective clinical trials associated with NCRT or NCT in EGJ/GC adenocarcinoma
Category | Author/year | No. of pts | Tumor stage | Study design | RT dose | Concurrent CT regime | CT regimes | Finding/ Clinical trial registration number |
|---|---|---|---|---|---|---|---|---|
Neoadjuvant radiotherapy | Shapiro [7] | 366 | T2–3N0/N +  | NCRT + S vs S | 41.4 Gy | TC | / | 7y OS: 41%vs28% (P < 0.05) |
Tian [21] | 150 | T2-4N0/N +  | NCRT + S vs S | 45 Gy | XELOX | / | 3yOS:63.4% vs 52.2%(P = 0.019) | |
Stahl [13] | 126 | cT3-4NxM0 | NCT + NCRT + S vs NCT + S | 30 Gy | EP | PF | 5yOS:39.5% vs 24.4%(P = 0.055) | |
Liu [22] | 36 | T4aN + /T4b | NCT + NCRT + S + CT | 45 Gy | S-1 | SOX | 2y:56% | |
Kim [23] | 42 | T3-4N0/N +  | NCT + NCRT + S + CT | 45 Gy | S-1 | SOX | 3y:75.5% | |
Perioperative chemotherapy | Cunningham [9] | 503 | T1-4N0/N +  | NCT + S + CT vs S | / | / | ECF | 5yOS:36.3%vs23% (P = 0.009) |
Ychou [10] | 224 | T1-4N0/N +  | NCT + S + CT vs S | / | / | CF | 5yOS: 38%vs24%(P = 0.02) | |
Al-Batran [8] | 716 | T2-4N0/N +  | NCT + S + CT vs NCT + S + CT | / | / | FLOT vs ECF/ECX | 5yOS:45%vs36% (P = 0.012) | |
Zhang [24] | 1094 | cT4aN + /cT4b | NCT + S + CT vs S + CT vs S + CT | / | / | SOX(Peri) vs SOX(post) vs XELOX(post) | 3yDFS:59.4% vs 56.5% vs 51.1%(arm1 vs arm3:P = 0·028) | |
Ongoing | TOPGEAR [25] | 752 | T3-4N0/N +  | NCT + NCRT + S + CT vs NCT + S + CT | 45 Gy | 5-Fu/Cap | ECF | NCT01924819 |
PREACT [26] | 682 | T3-4aN + /T4b | NCT + NCRT + CT vs NCT + S + CT | 45 Gy | S-1 | SOX | NCT03013010 | |
NEO-CRAG | 620 | T3N2-N3/T4aN + /T4b | NCT + NCRT + S + CT vs NCT + S + CT | 45 Gy | XELOX | XELOX | NCT01815853 | |
CRITICS II [27] | 207 | T2-4N0/N +  | NCT + NCRT + S vs NCRT + S vs NCT + S | 45 Gy | TC | DOC | NCT02931890 | |
CRADLE | 214 | T3-4N0/N +  | NCRT + S + CT vs S + CT | 50 Gy | SOX | SOX | NCT02193594 |